<DOC>
	<DOCNO>NCT00003250</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness fenretinide treat patient solid tumor .</brief_summary>
	<brief_title>Fenretinide Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose toxicity oral fenretinide patient solid malignant tumor . II . Determine pharmacokinetics fenretinide metabolite . III . Determine preliminary antitumor activity fenretinide patient population . IV . Determine recommend phase II start dose fenretinide . V. Determine whether fenretinide induces apoptosis clinical specimen . OUTLINE : This dose escalation study . Patients receive oral fenretinide daily day 1 , 8 9 three time day day 2-7 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Treatment continue 6 month follow complete remission . Accessible tumor biopsied day 8 . Cohorts 3-6 patient receive escalate dos fenretinide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 21 patient accrue study within 6-9 month .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove solid malignant tumor ( carcinoma sarcoma ) Not eligible know treatment regimen higher potential efficacy No history CNS tumor prior CNS metastases PATIENT CHARACTERISTICS : Age : 15 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/mL SGOT/SGPT great 2 time upper limit normal Renal : Creatinine great 1.5 mg/mL OR Creatinine clearance least 60 mL/min Cardiovascular : At least 6 month since acute myocardial infarction No congestive heart failure No New York Heart Association class III IV heart disease No clinically significant cardiac arrhythmia Pulmonary : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception No gastrointestinal bleeding bleeding tendency PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( least 6 week since nitrosoureas mitomycin ) recover No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : Not specify Other : No prior systemic retinoid therapy</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>